Abstract
Tumour cells are frequently characterized by over-expression of the polypeptide chain initiation factor eIF4E and current evidence supports the view that this factor contributes to malignant transformation. The availability of eIF4E for protein synthesis is regulated by the 4E binding proteins. The ability of these proteins to bind eIF4E is inhibited by multi-site phosphorylation, catalysed by the mammalian target of rapamycin (mTOR) and other protein kinases. This phosphorylation is stimulated by growth factors and nutrients whereas dephosphorylation is activated by a variety of cellular stresses. Over-expression of eIF4E promotes resistance to apoptosis, most likely as a result of enhanced synthesis of growth-promoting and anti-apoptotic proteins. Conversely, increased levels of the 4E binding proteins can promote apoptosis and suppress tumourigenicity. Consistent with this, the mTOR inhibitor rapamycin can enhance cell death, especially in cells in which signal transduction pathways that activate mTOR are hyperactive, and analogues of rapamycin are now in clinical use against a number of human cancers. Recent evidence suggests that phosphorylation may also reduce the stability of the 4E binding proteins, as a consequence of increased susceptibility to ubiquitination and subsequent degradation. Such accelerated degradation would result in greater availability of eIF4E for translation and the inhibition of apoptosis.
Keywords: Cancer, mTOR, oncogene, protein phosphorylation, therapy, translational control
Current Cancer Therapy Reviews
Title: Control of Protein Synthesis in Malignant Transformation - the Role of eIF4E and the eIF4E Binding Proteins in the Regulation of Apoptosis
Volume: 3 Issue: 3
Author(s): Michael J. Clemens, Androulla Elia and Constantina Constantinou
Affiliation:
Keywords: Cancer, mTOR, oncogene, protein phosphorylation, therapy, translational control
Abstract: Tumour cells are frequently characterized by over-expression of the polypeptide chain initiation factor eIF4E and current evidence supports the view that this factor contributes to malignant transformation. The availability of eIF4E for protein synthesis is regulated by the 4E binding proteins. The ability of these proteins to bind eIF4E is inhibited by multi-site phosphorylation, catalysed by the mammalian target of rapamycin (mTOR) and other protein kinases. This phosphorylation is stimulated by growth factors and nutrients whereas dephosphorylation is activated by a variety of cellular stresses. Over-expression of eIF4E promotes resistance to apoptosis, most likely as a result of enhanced synthesis of growth-promoting and anti-apoptotic proteins. Conversely, increased levels of the 4E binding proteins can promote apoptosis and suppress tumourigenicity. Consistent with this, the mTOR inhibitor rapamycin can enhance cell death, especially in cells in which signal transduction pathways that activate mTOR are hyperactive, and analogues of rapamycin are now in clinical use against a number of human cancers. Recent evidence suggests that phosphorylation may also reduce the stability of the 4E binding proteins, as a consequence of increased susceptibility to ubiquitination and subsequent degradation. Such accelerated degradation would result in greater availability of eIF4E for translation and the inhibition of apoptosis.
Export Options
About this article
Cite this article as:
Michael J. Clemens , Androulla Elia and Constantina Constantinou , Control of Protein Synthesis in Malignant Transformation - the Role of eIF4E and the eIF4E Binding Proteins in the Regulation of Apoptosis, Current Cancer Therapy Reviews 2007; 3 (3) . https://dx.doi.org/10.2174/157339407781368323
DOI https://dx.doi.org/10.2174/157339407781368323 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Catastrophic Antiphospholipid Syndrome - 20 Years Later
Current Rheumatology Reviews Cell Cycle Regulatory Kinase Modulators: Interim Progress and Issues
Current Topics in Medicinal Chemistry Stereoselective Pharmacodynamics and Pharmacokinetics of Proton Pump Inhibitors
Current Drug Metabolism Condensed and Hydrolysable Tannins as Antioxidants Influencing the Health
Mini-Reviews in Medicinal Chemistry Anti-cancer Research on Arnebiae radix-derived Naphthoquinone in Recent Five Years
Recent Patents on Anti-Cancer Drug Discovery Pharmacogenetics of the Cytochromes P450
Current Topics in Medicinal Chemistry Biological Agents Involved in Malignant Mesothelioma: Relevance as Biomarkers or Therapeutic Targets
Current Cancer Drug Targets Patent Selections
Recent Patents on Biomarkers Novel Approaches for Allergy
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Vasoactive Factors and Diabetic Retinopathy: Vascular Endothelial Growth Factor, Cycoloxygenase-2 and Nitric Oxide
Current Pharmaceutical Design Role of EGFR Monoclonal Antibodies in the Management of Non–small Cell Lung Cancer
Current Cancer Drug Targets Hypoxic Radiosensitizers and Hypoxic Cytotoxins in Radiation Oncology
Current Medicinal Chemistry - Anti-Cancer Agents Withdrawal Notice: Recent Developments in Anti-Cancer Activity of Compounds Containing the Thioether Group
Anti-Cancer Agents in Medicinal Chemistry Isolation, Purification and Characterization of a Novel Steroidal Saponin Cholestanol Glucoside from Lasiodiplodia theobromae that Induces Apoptosis in A549 Cells
Anti-Cancer Agents in Medicinal Chemistry Cancer Control by Phytochemicals
Current Pharmaceutical Design Computer-Aided Drug Design Methodologies Toward the Design of Anti-Hepatitis C Agents
Current Topics in Medicinal Chemistry Antibodies Against Muscarinic Receptors in Breast Cancer: Agonizing Tumor Growth
Current Immunology Reviews (Discontinued) Use of Anticancer Platinum Compounds in Combination Therapies and Challenges in Drug Delivery
Current Medicinal Chemistry The Therapeutic use of the Zonulin Inhibitor AT-1001 (Larazotide) for a Variety of Acute and Chronic Inflammatory Diseases
Current Medicinal Chemistry Non-Invasive Monitoring of Hsp70 Promoter Activity Using Firefly Luciferase and Cell Viability of Three Tumor Cell Lines Exposed to Different Levels of Heat
Current Medical Imaging